Clinical Trials
25 trialsNCT04774718 2026-06-04
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05386108 2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06840886 2026-05-14
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Phase 1 Recruiting
NCT03554707 2026-05-08
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
SynerGene Therapeutics, Inc.
Phase EARLY_PHASE1 Withdrawn
NCT05599984 2026-05-07
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT05081180 2026-05-01
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
EMD Serono
Phase 1 Active not recruiting
NCT06441331 2026-05-01
KinLET
ITM Solucin GmbH
Phase 1 Recruiting
NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT07100730 2026-04-16
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06357377 2026-01-14
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Neonc Technologies, Inc.
Phase 1 Not yet recruiting
NCT04773782 2026-01-13
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
Phase 1/2 Completed
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT02684838 2025-11-10
VIGILANT
Arbor Pharmaceuticals, Inc.
Completed
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT05270707 2025-09-24
HyperArc Registry Study
Varian, a Siemens Healthineers Company
Completed
NCT05406167 2025-08-15
PREMIER
RefleXion Medical
Recruiting
NCT07098806 2025-08-01
CA2024-LM-001
Plus Therapeutics
Phase 1 Recruiting
NCT05235074 2025-07-25
OH2 Oncolytic Viral Therapy in Central Nervous System Tumors
Binhui Biopharmaceutical Co., Ltd.
Phase 1/2 Recruiting